Skip to main navigation
MIRUM

Header Menu

  • Who We Are
    • About Mirum
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • Maralixibat
    • Volixibat
    • Publications & Presentations
  • Patients & Families
    • Clinical Trials
    • Expanded Access
    • Progressive Familial Intrahepatic Cholestasis (PFIC)
    • Alagille Syndrome (ALGS)
    • Biliary Atresia (BA)
    • Intrahepatic Cholestasis of Pregnancy (ICP)
    • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
    • News Releases
    • Events and Presentations
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filing
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us
  • Menu

Investor Relations

  • News Releases
  • Events and Presentations
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Management
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
  • Shareholder Services
    • Investor FAQs
    • Contact IR
    • Email Alerts

Investor Tools

  • Print

    Print

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Search

    Search

  • Contact IR

    Contact IR

  • Email Page

    Email Page

Investor FAQs

Investor FAQs

Show All

When was Mirum founded?

Mirum was founded in 2018.

Where is Mirum incorporated?

Mirum is incorporated in the state of Delaware.

Where is Mirum’s corporate HQ?

950 Tower Lane, Suite 1050, Foster City, CA 94404.

Who are the members of Mirum’s board of directors?

You can view our board of directors by visiting the “Board of Directors” section of our website.

Who are the members of Mirum’s management team?

You can view our management team by visiting the “Management Team” section of our website.

When is Mirum’s fiscal year-end?

Mirum’s fiscal year ends December 31.

Who is Mirum’s independent registered accounting firm?

Ernst & Young LLP.

On which exchange is Mirum listed and what is the ticker symbol?

Mirum is traded on the Nasdaq Global Market under the symbol “MIRM”.

When did Mirum go public?

Mirum went public in July 2019.

How can I purchase shares of Mirum?

As Mirum trades publicly on the NASDAQ, shares can be purchased through a stockbroker of your choice.

Does Mirum have a direct stock purchase plan?

Mirum does not currently offer a direct stock purchase plan.

Does Mirum pay dividends and have a dividend reinvestment program?

Currently, Mirum does not offer a dividend or a dividend reinvestment program.

What is Mirum’s CUSIP number?

Mirum’s CUSIP number is 604749 101.

Who is Mirum’s transfer agent and how do I contact them?

Mirum’s transfer agent is the American Stock Transfer and Trust Company (AST). You can find more information about how to contact American Stock Transfer at: http://www.amstock.com/main/nav_contactus.asp.

How can I replace my lost stock certificate?

Please contact our transfer agent at: http://www.amstock.com/main/nav_contactus.asp. AST can look up your records and make any necessary adjustments. There is a fee involved for replacing lost certificates.

How can I get a copy of your Annual Report or any other investor materials such as an Investor Relations Kit or 10-K?

Quarterly & Annual Reports and other investor materials, when available, can be found in “Financials & Filings” in the “Investor Relations” section of our corporate website. Additionally, all SEC filings can be accessed directly from the SEC at www.sec.gov.

Where can I find recent Mirum press releases?

You can view our recent press releases by visiting the “News Releases” section of our website.

Who can I contact if I am a member of the media?

For media inquiries please send an email to media@mirumpharma.com.

Where can I find more information on Mirum’s R&D programs?

You can view more information on our development programs by visiting the “Our Medicines” section of our website.

How do I contact Investor Relations with a question or request?

For investor related questions please send an email to ir@mirumpharma.com.

How can I sign up to receive Mirum’s press releases and other company information?

Please visit the “Email Alerts” section of our website and fill out our web-form to be added to our distribution list.

If I have questions regarding Mirum that have not been answered, whom should I contact?

You can reach Investor Relations by calling (650) 667-4085 or sending an email to ir@mirumpharma.com.

Header Menu

  • Who We Are
  • About Mirum
  • Leadership
  • Board of Directors
  • Programs
  • Pipeline
  • Maralixibat
  • Volixibat
  • Publications & Presentations
  • Patients & Families
  • Clinical Trials
  • Expanded Access
  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Alagille Syndrome (ALGS)
  • Biliary Atresia (BA)
  • Intrahepatic Cholestasis of Pregnancy (ICP)
  • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
  • News Releases
  • Events and Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Shareholder Services
  • Careers
  • Contact Us
© 2021 – Mirum Pharmaceuticals, Inc.
Scroll to top
  • Facebook
  • Twitter
  • LinkedIn